IP Verse

Pharmaceutical Compositions Having Desirable Bioavailability - EP3042646

The patent EP3042646 was granted to Alcon Research on May 10, 2017. The application was originally filed on Mar 13, 2009 under application number EP15202422A. The patent is currently recorded with a legal status of "Revoked".

EP3042646

ALCON RESEARCH
Application Number
EP15202422A
Filing Date
Mar 13, 2009
Status
Revoked
Jul 19, 2024
Grant Date
May 10, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ACTREVOFeb 12, 2018BRAEUNING SCHUBERT PATENTANWALTE GBRWITHDRAWN
GENERICS UK TRADING MYLANFeb 9, 2018GILL JENNINGS & EVERYADMISSIBLE
POLPHARMAFeb 9, 2018BIRD & BIRDADMISSIBLE
BAUSCH & LOMB INCORPORATEDFeb 7, 2018MAIWALDADMISSIBLE
INSTONEFeb 1, 2018APPLEYARD LEESADMISSIBLE

Patent Citations (37) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONJP2003104870
DESCRIPTIONUS2002122831
DESCRIPTIONUS3931319
DESCRIPTIONUS4027020
DESCRIPTIONUS4407791
DESCRIPTIONUS4522806
DESCRIPTIONUS4525346
DESCRIPTIONUS4836986
DESCRIPTIONUS5037647
DESCRIPTIONUS5221664
DESCRIPTIONUS5300287
DESCRIPTIONUS5320843
DESCRIPTIONUS5741817
DESCRIPTIONUS5817277
DESCRIPTIONUS6017861
DESCRIPTIONUS6034043
DESCRIPTIONUS6319464
DESCRIPTIONUS6348190
DESCRIPTIONUS6482799
DESCRIPTIONUS6503497
DESCRIPTIONWO9109523
OPPOSITIONEP1321144
OPPOSITIONEP1666043
OPPOSITIONUS2002009507
OPPOSITIONUS6011062
OPPOSITIONUS6743439
OPPOSITIONWO0003736
OPPOSITIONWO2008042619
OPPOSITIONWO2008052031
OPPOSITIONWO9729752
SEARCHEP1547599
SEARCHEP2123278
SEARCHUS2004082660
SEARCHUS6743439
SEARCHWO0003736
SEARCHWO9819680
SEARCHWO9841208

Non-Patent Literature (NPL) Citations (25) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Bergman et al., "21-994 Travoprost (TRAVATAN® Z/AP/AF; TBD)", Clinical Pharmacology and Biopharmaceutics Review(s), (20051118), vol. 28, no. 4, XP055605920-
OPPOSITION- "Chapter 1, Basic Science of Ocular Pharmacology", NEAL L. BURSTEIN, Clinical Ocular Pharmacology, (19890000), pages 3 - 10-
OPPOSITION- chapter 43, chapter 43, David B.Troy, Ophthalmic Preparations, (20060000), pages 861-862 - 870, XP055460066-
OPPOSITION- MSDS for HCO-40 - Croduret 40-SS-(RB, (20150700), XP055460080-
OPPOSITION- "Ophthalmic Preparations", Remington: The Science and Practice of Pharmacy, Philadelphia, PA, (20060000), page 861, 862, 870, XP055460066-
OPPOSITION- R. A. LEWIS et al., "Travoprost 0.004% With and Without Benzalkonium Chloride: A comparison of Safety and Efficacy", JGloucoma, (20070100), vol. 16, pages 98 - 103, XP055462693-
OPPOSITION- RICHARD W . YEE, "The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review", Curr Opin Ophthalmol, (20070300), vol. 18, no. 2, pages 134 - 9, XP055456925-
OPPOSITION- "SofZia preservative system meets United States Pharmacopoeia standards", Ophthalmology Magazine, (20070400), pages 1 - 8, XP055460043-
OPPOSITION- "Toxicity issues", V. STELLA et al., Prodrugs: Challenges and Rewards Part 1, (20070312), page 663, XP055460046-
OPPOSITION- "Travatan®Z Pharmacological Review - NDA 21-994", Department Of Health And Human Services, (20060302), XP055456902-
OPPOSITION- "TRAVATAN-Z (travoprost ophthalmic solution) 0.004%", Alcon Laboratories, Inc., (20060000), pages 1 - 12, XP055462668-
OPPOSITION- "TRAVATAN-Z (travoprost ophthalmic solution) 0.004%", Alcon Laboratories, Inc., (20060900), pages 1 - 12, XP055462668-
OPPOSITION- YEE, "The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review", Current Opinion In Ophthalmology, (20070000), vol. 18, pages 134 - 139, XP055456925-
OPPOSITION- Zhou Chen et al, "TRAVATAN-ZO pharmacology review 21-1994", Center for Drug Evaluation and Research, (20060302), pages 1 - 27, XP055462660-
OPPOSITION- Zhou Chen Et Al, "TRAVATAN-Z pharmacology review 21-1994", Center for Drug Evaluation and Research, (20060900), pages 1 - 27, XP055462660-
OPPOSITION- "Effects of Benzalkonium Chloride-Preserved, Polyquad-Preserved, and sofZia-Preserved Topical Glaucoma Medications on Human Ocular Epithelial Cells", Adv Ther, (20100000), vol. 27, no. 11, pages 1 - 9, XP055097387
OPPOSITION- M. FABRIZIO SAETTONE et al., "Evaluation of ocular permeation enhancers: in vitro effects on corneal transport of four ß-blockers, and in vitro/in vivo oxic activity", International Journal of Pharmaceutics, (19960000), vol. 142, pages 103 - 113, XP009114267
OPPOSITION- Kaur et al., "Penetration Enhancers and Ocular Bioadhesives: Two New Avenues for Ophthalmic Drug Delivery", (2002), vol. 28, pages 353 - 369, XP055484424
OPPOSITION- LABBÉ A. et al., "Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-i: an experimental study", J Ocul Pharmacol Ther, (20060800), vol. 22, no. 4, pages 267 - 78, XP055264197
OPPOSITION- LABBE et al., "Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study", J Ocul Pharmacol Ther, (20060800), vol. 22, no. 4, pages 267 - 78, XP055264197
OPPOSITION- LABBE ET AL. et al., "Comparison of Toxicological Profiles of Benzalkonium Chloride and Polyquaternium-1: An Experimental Study", J of Ocular Pharm and Ther, (20060000), vol. 22, no. 4, pages 267 - 278, XP055264197
OPPOSITION- BAUDOUIN, C. et al., "In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost", Invest Ophthalmol Vis Sci, (20070900), vol. 48, no. 9, pages 4123 - 8, XP002607568
OPPOSITION- BAUDOUIN et al., "In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost", IOVS, (20070900), vol. 48, no. 9, XP002607568
OPPOSITION- C. BADOUIN et al., "In Vitro Studies of Antiglaucomatous Prostaglandin Analogues: travoprost with and without Benzalkonium Chloride and Preserved Latanoprost", Investigative Ophthalmology & Visual Science, (20070900), vol. 48, no. 9, pages 4123 - 4128, XP002607568
OPPOSITION- "Quantitative evaluation of the corneal epithelial barrier: effect of artificial tears and preservatives", Current Eye Research, (19910000), vol. 10, no. 7, pages 645 - 656, XP055265030

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents